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Mutations of the FOXP2 gene cause a severe speech and language disorder, providing a
molecular window into the neurobiology of language. Individuals with FOXP2 mutations
have structural and functional alterations affecting brain circuits that overlap with
sites of FOXP2 expression, including regions of the cortex, striatum, and cerebellum.
FOXP2 displays complex patterns of expression in the brain, as well as in non-
neuronal tissues, suggesting that sophisticated regulatory mechanisms control its
spatio-temporal expression. However, to date, little is known about the regulation
of FOXP2 or the genomic elements that control its expression. Using chromatin
conformation capture (3C), we mapped the human FOXP2 locus to identify putative
enhancer regions that engage in long-range interactions with the promoter of this gene.
We demonstrate the ability of the identified enhancer regions to drive gene expression.
We also show regulation of the FOXP2 promoter and enhancer regions by candidate
regulators – FOXP family and TBR1 transcription factors. These data point to regulatory
elements that may contribute to the temporal- or tissue-specific expression patterns
of human FOXP2. Understanding the upstream regulatory pathways controlling FOXP2
expression will bring new insight into the molecular networks contributing to human
language and related disorders.
Keywords: FOXP2, enhancer elements, Genetic, regulation of gene expression, language, language disorders,
TBR1
INTRODUCTION
FOXP2 is the first and most well-studied gene to be implicated in human speech and language
skills. Heterozygous mutations of the FOXP2 gene cause a severe speech and language disorder
characterized by childhood apraxia of speech (CAS) and accompanied by expressive and receptive
language problems (Vargha-Khadem et al., 1995; Watkins et al., 2002). The first FOXP2 point
mutation to be identified was a disruptive missense variant inherited by all affected members of a
large three-generation pedigree, known as the KE family (Lai et al., 2001). Further mutations have
been found in similarly affected individuals including missense and nonsense mutations disrupting
the protein sequence (MacDermot et al., 2005; Reuter et al., 2017) and larger structural changes that
affect the FOXP2 locus such as; whole gene deletions (Feuk et al., 2006; Zeesman et al., 2006; Lennon
et al., 2007; Palka et al., 2012; Rice et al., 2012; Zilina et al., 2012), chromosomal rearrangements
disrupting the gene coding sequence (Lai et al., 2001; Feuk et al., 2006; Shriberg et al., 2006), and a
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small intragenic deletion leading to a premature stop codon
(Turner et al., 2013; Reuter et al., 2017). Structural mutations
near the FOXP2 locus that do not disrupt the coding sequence
have also been identified in individuals with speech and language
problems (Feuk et al., 2006; Adegbola et al., 2015; Moralli
et al., 2015). Some of these mutations have been hypothesized
to affect non-coding regulatory elements of FOXP2 and could
therefore exert their effects by influencing expression of the gene.
For example, in a child with delayed speech development, a
complex structural mutation was found including a balanced
inversion with a breakpoint downstream of FOXP2 (Moralli et al.,
2015). Downstream of this breakpoint, a functional enhancer
was identified that was suggested to alter FOXP2 expression
and thus contribute to the disorder (Becker et al., 2015).
Therefore, while it is clear that disruptions of the FOXP2 coding
region result in speech/language deficits, it may also be the
case that dysregulation of this gene can contribute to similar
phenotypes.
Patients with FOXP2 mutations display alterations affecting
both structural and functional brain features (Vargha-Khadem
et al., 1998; Watkins et al., 2002; Belton et al., 2003; Liegeois
et al., 2003, 2011). Voxel-based morphometry has identified
altered gray matter density in cortical areas (including posterior
superior temporal gyrus, angular gyrus, and inferior frontal
gyrus), the caudate nucleus, putamen and cerebellar lobule
VIIIB (Vargha-Khadem et al., 1998; Watkins et al., 2002; Belton
et al., 2003). Functional activation differences during various
language-related tasks have been observed in select cortical
regions (including the inferior frontal gyrus), the caudate nucleus
and the putamen (Belton et al., 2003; Liegeois et al., 2003;
Pinel et al., 2012). The neural sites of alteration in these
studies overlap with the regions of the brain where FOXP2 is
expressed, suggesting that loss of functional FOXP2 in these
structures may be contributing to the neural and behavioral
phenotypes.
FOXP2 expression patterns have been characterized in the
embryonic human brain, as well as in the embryonic and
adult mouse brain (Ferland et al., 2003; Lai et al., 2003).
These studies showed overlapping and complex patterns of
expression in developing cortical, subcortical, midbrain and
hindbrain regions. FOXP2/Foxp2 expression was observed in
the cortex (deep layers), basal ganglia (medium spiny neurons),
thalamus, hypothalamus, inferior colliculus, medulla (inferior
olive), and cerebellum (Purkinje cells). Many of the FOXP2
positive brain regions are involved in motor control and
motor learning, for example cortico-striatal-thalamic and olivo-
cerebellar circuitry (Vargha-Khadem et al., 2005). However,
FOXP2/Foxp2 expression is not restricted to the brain and it
is also found in the spinal cord, lungs, heart, and intestines
(Shu et al., 2001; Morikawa et al., 2009). This suggests that a
complex set of regulatory mechanisms control the expression of
FOXP2. Different promoters and/or enhancers may be driving
expression in neuronal versus non-neuronal tissue, directing
expression in specific subsets of cells within a tissue, and ensuring
it is switched on only at the appropriate developmental time
points. Although these complex expression patterns of FOXP2
were first described more than a decade ago, there is still
very little known about the mechanisms by which the gene is
regulated.
Transcription of FOXP2 may be initiated at one of at least
four transcriptional start sites (TSSs) (Bruce and Margolis,
2002; Schroeder and Myers, 2008). These alternative TSSs
are utilized differently across different cells types and tissues;
however, all but one are predicted to yield the same protein
product (Bruce and Margolis, 2002; Schroeder and Myers,
2008). Thus, the role of these alternative TSSs may be
to control when, where and how much FOXP2 protein is
expressed, leading to cell type, tissue or developmental stage
specific expression (Bruce and Margolis, 2002; Schroeder and
Myers, 2008). A small number of putative enhancer elements
contributing to FOXP2 regulation have previously been identified
in human and animal systems. For example, a putative enhancer
element was identified in intron 8 of human FOXP2 that was
bound and regulated by the POU3F2 transcription factor (TF)
(Maricic et al., 2013). A POU3F2 binding site in this enhancer
was altered via a nucleotide change during the evolution of
modern humans, with the ancestral allele acting as a stronger
driver of reporter gene expression in experimental assays, as
compared to the derived allele (Maricic et al., 2013). Three
putative enhancers located upstream, downstream and within
intron 2 of the zebrafish FoxP2 coding region were shown
to drive reporter gene expression in vivo (Bonkowsky et al.,
2008). The upstream and intron 2 enhancers were directly
bound by the lef1 TF and lef1 knockdown resulted in loss of
FoxP2 expression in the midbrain and hindbrain of zebrafish
embryos (Bonkowsky et al., 2008). To date, no comprehensive
assessment of human FOXP2 regulatory regions has been
performed.
To better understand the regulatory mechanisms controlling
FOXP2 expression in humans, we mapped putative enhancer
regions at and around the FOXP2 locus. Using chromatin
conformation capture (3C) we identified genomic regions that
engaged in long-range interactions with the FOXP2 promoter,
indicating possible enhancer activity. Reporter gene assays
demonstrated that some of these putative enhancer regions were
able to drive expression. Moreover we investigated regulation
of the FOXP2 promoter and active enhancer regions by FOXP
family and TBR1 TFs. These data give insight into the upstream
molecular networks and cis genomic regions that may influence
the spatio-temporal regulation of FOXP2.
MATERIALS AND METHODS
Cell Culture
HEK293, SH-SY5Y, IMR32, SK-N-AS, and KELLY cell lines
were purchased from HPA Culture Collections (England, UK),
SK-N-MC and PFSK1 were purchased from ATCC (Virginia,
USA). The EBV transformed lymphoblast cell lines GM22671
and GM22737 were obtained from Coriell Cell Repositories (NJ,
USA). All cell lines were cultured at 5% CO2 and 37◦C in the
appropriate culture media. Adherent (non-EBV) cell lines were
supplemented with 10% fetal bovine serum (Invitrogen, CA,
USA) and 1% penicillin/streptavidin (Invitrogen). EBV cell lines
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were supplemented with 15% fetal bovine serum (Invitrogen)
and 1% penicillin/streptavidin (Invitrogen). The culture medium
used to grow HEK293 cells was DMEM (Invitrogen), SK-N-
MC and IMR32 were grown in MEM (Invitrogen) supplemented
with 2 mM L-glutamine (Invitrogen), and SH-SY5Y and SK-
N-AS were grown in DMEM:F12 (Invitrogen) supplemented
with 2 mM L-glutamine and 1% non-essential amino acids
(Invitrogen). KELLY, PFSK1, GM22671, and GM22737 were
grown in RPMI 1640 media (Sigma-Aldrich, MO, USA)
supplemented with 2 mM glutamine.
FOXP2 Expression Analysis (qPCR)
Cells were lysed in TRIzol (Invitrogen) and RNA was extracted
using RNeasy Spin Columns (Qiagen, NRW, Germany). Reverse
transcription was performed on 2000 ng of RNA using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
CA, USA) using random primers, according to the manufacturer
protocol. Relative expression levels were determined by real-time
quantitative PCR (qPCR) using iQ SYBR Green Supermix
(Bio-Rad, CA, USA). FOXP2 mRNA was amplified using exon
spanning primers with the forward primer in exon 5 (5′-AC
AGCATCCTGGAAAGCAAG-3′) and reverse primer in exon 6
(5′-ATGGAGATGAGTCCCTGACG-3′). The expression of the
GAPDH housekeeping gene was quantified using the following
primers: forward 5′-AAGGTGAAGGTCGGAGTCAAC-3′,
reverse: 5′-GGGGTCATTGATGGCAACAATA-3′. Differential
expression (dCt) was determined by normalizing the Ct value
of FOXP2 mRNA to the Ct value of GAPDH mRNA. We then
compared the FOXP2 expression across all the cell lines, using
the expression level in HEK293 cells as reference (using the ddCt
method) (Livak and Schmittgen, 2001).
Chromatin Immunoprecipitation (ChIP)
A total of 2.5 × 107 cells were crosslinked with 0.5%
formaldehyde for 10 min at room temperature (RT). After
quenching the reaction with 125 mM glycine, the lysate was
sonicated using 12 cycles of sonication (30 s on/30 s off) in a
Bioruptor (Diagenode, Belgium), set to “high” frequency. 2 µl
of POLR2A antibody (Diagenode, Cat# AC-055-100) was used
to immunoprecipitate chromatin fragments, rotating overnight
at 4◦C. Purified DNA fragments were eluted in 50 µl TE.
Enrichment of target DNA fragments was detected via qPCR
using the iQ SYBR Green Supermix (Bio-Rad) on 2 µl sample
DNA according to the manufacturer’s protocol. Primer sequences
for each target fragment are listed in Supplementary Table S1.
Statistical significance was assessed using pairwise ANOVA and
post hoc Tukey test.
Chromatin Conformation Capture (3C)
We used a modified 3C protocol based on Hagege et al. (2007).
1 × 106 cells were crosslinked using 0.5% formaldehyde for
10 min at RT. Cells were lysed via homogenisation using a dounce
tissue grinder. Chromatin was digested overnight at 37◦C with
400 units of BglII (New England Biolabs, MA, USA). Following
this, another 200 units of BglII restriction enzyme were added to
the reaction for 1 h at 37◦C. Restriction enzymes were inactivated
by adding SDS (2% final) and incubation for 30 min at 37◦C
followed by addition of Triton X-100 (2% final) to quench SDS.
Fragments were ligated using 50 units of T4 Ligase (Roche,
Switzerland) in 5 ml reaction volume at 16◦C overnight (ligation
was performed in a high volume to favor ligation events between
cross-linked DNA strands). Cross links were reversed at 65◦C
overnight in the presence of Proteinase K (0.5 mg/ml), and
samples were then purified via phenol extraction.
Sample quantification was performed via real-time qPCR,
using iQ SYBR Green (Bio-Rad) and compared against a
standard curve (range 5–1000 ng) generated using human
genomic DNA (Novagen). Quantification of specific ligation
products was done by TaqMan real-time PCR using SsoFast
Probes Supermix (Bio-Rad) according to the manufacturer’s
protocol. Primer sequences are listed in Supplementary
Table S2. The sequence of the custom made MGB-TaqMan
probe was 5′-GATCTCTTAAACCACTGGGAATTCA-3′
(Applied Biosystems) and matches the sequence on chromosome
7 from nucleotide 113,732,166 to 113,732,190 (reference genome
hg19). The delta Ct value for each ligation product was calculated
by subtracting the Ct value from the average Ct value of the same
ligation product in EBV-lymphoblast cell lines. If the ligation
product could not be detected in the EBV cell lines, a value of
40 was subtracted, which is equal to the lowest detected ligation
product in the EBV cell lines. From the Ct values, we calculated
the relative amount of starting ligation products by raising the
negative Ct value to the power of two, which is a measure of the
interaction frequency. Finally, we derived the relative interaction
frequency by normalizing to the ligation product with the lowest
variation across all cell lines (primer at−11 kb).
The anchor point primer and TaqMan probe were designed
to match the restriction fragment that contains the first
transcriptional start site (TSS1) of the FOXP2 gene. Detection
primers were designed to be complementary to the 5′ end of
BglII restriction fragments so that the amplicons of the ligation
products were not bigger than 250 bp. Primers were designed to
match genomic fragments up to 106 kb upstream and 1,391 kb
downstream of TSS1, spanning a total of 1,497 kb around the
FOXP2 gene locus. Within this genomic region, there are 428
restriction fragments produced by BglII digestion. Primers were
designed for 50 of these fragments. The linear amplification range
of the primers was assessed using standard curves of the PCR
reaction on 3C samples with standardized concentrations (50,
125, 250, 500, 750, and 1,000 ng). Forty-five primers passed
this quality control step, and they covered fragments of a
total size of 218 kb. All primers are listed in Supplementary
Table S2.
Statistical significance of the difference of 3C crosslinking
frequencies to LBV-lymphoblast cell crosslinking frequencies was
assessed using two-tailed student t-tests. P-values were corrected
for the number of investigated interactions (45) using Benjamini-
Hochberg correction.
Luciferase Reporter Assays
Regulatory sequences were cloned from healthy human genomic
DNA (Novagen) using Advantage 2 Polymerase kit (Clontech,
CA, USA) according to the manufacturer’s protocol. Cloning
primers are listed in Supplementary Table S3. PCR products
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were first cloned into the pCR2.1-TOPO vector using the TOPO
TA Cloning Kit (Invitrogen), then subcloned into pGL4.23
(Promega) and confirmed via Sanger sequencing. Promoter
elements were subcloned using SacI (5′) and XhoI (3′) restriction
sites. Enhancer elements were subcloned using KpnI (5′) and
XhoI (3′).
For luciferase assays, HEK293 or SK-N-MC were transfected
using GeneJuice Transfection Reagent (Merck Millipore, MA,
USA), with 48 ng of pGL4.23-Enhancer and 6 ng of pGL4-hRLuc-
TK control plasmid (Promega, WI, USA). Luciferase enzymatic
activity was determined using the Dual-Luciferase Assay System
(Promega) in a TECAN Infinite 2002 plate reader (TECAN,
Switzerland). The promoter and enhancer activities were each
detected in three biological replicates. To test the effects of TFs
on the enhancers and promoters, pGL4.23-enhancer/promoter
and TF over-expression plasmids were co-transfected in HEK293
cells. FOXP1, FOXP2, and FOXP4 were overexpressed from a
pcDNA3 vector (Vernes et al., 2006). TBR1 and CASK were
overexpressed from a pYFP vector (Deriziotis et al., 2014).
Cells were transfected with 2 ng of pGL4.23-promoter/enhancer,
2 ng of pGL4.74-hRLuc-TK and 10 ng of the individual TF
plasmid.
To determine the basal activities, the relative firefly luciferase
activities of the promoter/enhancer elements were compared
to the firefly luciferase activity of the empty (minP) construct
within the same cell lines. Statistical significance of the
basal enhancer and promoter activities were assessed using
pairwise ANOVA and post hoc Least Significant Difference
(LSD) tests. The luciferase activity was compared between
co-transfection of TFs or empty pcDNA4 vectors. We
routinely used pcDNA4 as control because co-transfection
of empty pYFP vectors with the promoter and enhancer
constructs yielded comparable results (data not shown). The
difference between empty plasmid and TF overexpression was
assessed per individual element and the statistical significance
was assessed using two-way ANOVA and post hoc LSD
tests.
RESULTS
Identification of Active FOXP2 Promoters
in Human Cell Lines
To map FOXP2 enhancer regions in human cells, it was
first necessary to determine which cell lines express FOXP2
endogenously and which promoter(s) may drive this endogenous
expression. We tested endogenous expression of FOXP2 in six
human neuroblast cell lines (SK-N-MC, PFSK1, KELLY, SK-N-
AS, IMR32, and SH-SY5Y), and one kidney derived cell line
(HEK293). HEK293 cells are already known to endogenously
express FOXP2 and have been previously used by us and others
to study its function (Vernes et al., 2006; Fu et al., 2014;
Sin et al., 2015; Estruch et al., 2016). We compared FOXP2
expression in the six neuroblast and two EBV-transformed
lymphoblast cell lines (GM22671 and GM22737), relative to
HEK293 cells (Figure 1). We included EBV cell lines here
as they would be used to control for chromatin interactions
FIGURE 1 | Endogenous expression of FOXP2 in human cell lines.
Endogenous expression of FOXP2 mRNA in HEK293, SK-N-MC, PFSK1,
KELLY, IMR32, SK-N-AS, SH-SY5Y, and EBV cell lines (GM22671 and
GM22737) as determined by RT-qPCR. A no template control (NTC) was also
included. All expression levels have been normalized to HEK293 levels as this
cell line is well established to show strong expression of FOXP2.
in our subsequent 3C experiments. SK-N-MC cells showed
comparable FOXP2 expression levels to HEK293 cells, whereas
PFSK1 expression was approximately 80% lower. None of the
other neuroblast lines expressed detectable levels of FOXP2.
Expression in EBV cell lines was detectable, but extremely low
(Figure 1).
Transcription of the human FOXP2 gene may be initiated
from one of four previously described TSSs (Figure 2A),
which display cell line- and tissue-specific activity (Schroeder
and Myers, 2008). To identify which of these TSSs were
active in HEK293 cells we first assessed RNA Polymerase II
(PolII) occupancy followed by luciferase reporter assays of the
putative promoter fragments. PolII occupancy is an indicator
of transcription initiation and active promoter regions (Bonn
et al., 2012; Core et al., 2012; Le Martelot et al., 2012). To map
PolII occupancy across the four alternative TSSs we performed
PolII chromatin immunoprecipitation (ChIP), followed by qPCR
of the pulled down DNA fragments. Ten qPCR primers were
designed, spanning the four alternative TSSs (Figure 2A;
Supplementary Table S1). Primers complementary to a region
that is not bound by PolII (within exon 2 of the myoglobin
gene, as shown in previous studies) were used as a negative
control. Significant enrichment was observed for DNA fragments
spanning primer pairs 2 and 3 (adjacent to TSS1) and primer
pair 9 (adjacent to TSS4), indicating that these regions may be
active promoters (Figure 2B). Primer pair 2 was a good candidate
for the location of an active promoter as it was just upstream
of TSS1, which was previously shown to be active in HEK293
cells (Schroeder and Myers, 2008). As such we also tested
PolII occupancy at the position of primer pair 2 in SK-N-MC
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FIGURE 2 | Promoter 1 of FOXP2 drives endogenous expression. (A) Linear representation of the genomic location on chromosome 7q31, encompassing the 5′
end of the FOXP2 gene. The first exons of FOXP2, from exon S1 to exon2 are shown as white boxes with promoters and transcriptional start sites (TSSs) at exon
S1, 1, 1b and 2 indicated by arrows. The first upstream ATG start codon is located in exon 2. The relative location of the ten qPCR primer pairs used for RNAPolII
ChIP are indicated by blue lines and numbered 1–10. (B) RNA polymerase II (RNAPolII) occupancy at the promoter regions of FOXP2, as measured by ChIP-qPCR.
The relative PolII occupancy in HEK293 cells is shown for each primer pair and for myoglobin exon 2, which is used as a negative control. RNA-PolII occupancy is
normalized to a positive control region at the GAPDH promoter. (C) Normalized PolII occupancy at TSS1 primer pair 2 and myoglobin exon 2 (negative control) is
shown for the cell lines HEK293, SK-N-MC, KELLY, and IMR32. The qPCR was performed in duplicate. Significance was determined in comparison to the negative
control by ANOVA followed by post hoc Tukey tests. ∗p < 0.05. (D) Schematic representation of the firefly luciferase constructs tested in (E). Promoter elements
(TSS) were cloned to replace the minimal promoter (minP) in pGL4.23. (E) Relative luciferase activity of promoter elements driving firefly luciferase gene expression in
HEK293 and SK-N-MC cells. The promoter constructs were co-transfected with the pGL4.74 control plasmids expressing the renilla luciferase under the control of a
herpes simplex virus thymidine kinase (HSV-TK) promoter. The firefly luciferase signal was divided by the renilla signal to derive the relative luciferase activity. The
activity for each luciferase construct was normalized for the activity observed for the minimal promoter (minP). The constructs were measured in two independent
experiments in a total of six biological replicates. The statistical significance of the difference between each construct and minP was determined with two-way
ANOVA and post hoc LSD testing. ∗p < 0.05, ∗∗p < 0.001.
neuron-like cells that endogenously express FOXP2, and two
neuron-like cell lines that do not express endogenous FOXP2
(KELLY and IMR32 cell lines). PolII was strongly enriched
in SK-N-MC cells (∼8-fold stronger enrichment compared to
HEK293 cells), but was not enriched in KELLY or IMR32 cells
(Figure 2C).
Since there was PolII enrichment just upstream of TSS1 in the
two FOXP2 positive cell lines tested (HEK293 and SK-N-MC),
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we went on to determine if TSS1 was an active promoter and
could drive reporter gene expression in both cell lines. We cloned
a 1,791 bp fragment that spanned 1,547 bp upstream of TSS1
(including the primer regions 1 and 2) and 244 bp downstream
(including part of the 5′UTR of FOXP2 but excluding the start
codon). This fragment was placed upstream of a firefly luciferase
reporter gene to act as its promoter (Figure 2D). We also
compared expression from constructs containing comparable
fragments spanning TSS2 (∼4.1 kb fragment) and TSS3 (∼1 kb
fragment). These regions had not shown PolII occupancy in
HEK293 cells, suggesting they are inactive promoters and thus
they are not expected to be able to drive luciferase expression
above the level of the baseline control. The baseline control was
an equivalent construct containing a minimal promoter region
(minP) (Figure 2D). Details of the cloned elements are given in
Table 1. Measurement of relative luciferase activity recapitulated
the pattern observed for PolII occupancy. The fragment spanning
TSS1 resulted in significantly stronger reporter gene expression
in both HEK293 and SK-N-MC lines, but the effect was ∼8-
fold stronger in SK-N-MC cells (Figure 2E). The ability of TSS1
to drive expression in HEK293 cells is consistent with previous
reports (Schroeder and Myers, 2008). The fragments spanning
TSS2 and TSS3 did not increase luciferase activity above the levels
of the minP baseline control, confirming them as inactive regions
in these cell lines. These data suggest that TSS1 represents an
active FOXP2 promoter region in HEK293 and SK-N-MC cell
lines. As such we went on to use TSS1 to identify putative FOXP2
enhancers that make contact with this promoter region.
Identification of Putative FOXP2
Enhancers via Chromatin Conformation
Capture (3C)
Identifying enhancer regions is challenging as they can be
found at distances of up to 1 Mb from the genes they regulate
(Pennacchio et al., 2013). However, in order to contribute to gene
regulation, enhancers loop around to make physical contact with
promoter regions, facilitating the formation of protein complexes
that drive gene expression. Chromatin conformation capture
(3C) is a method that allows these three-dimensional contacts
to be identified (Figures 3A–E). In brief, the method involves
cross linking cells to preserve endogenous three-dimensional
structures (Figure 3B), digesting the DNA using a restriction
enzyme with evenly spaced digestion sites (in our case BglII) to
create overhangs in the looped DNA (Figure 3C), and directly
ligating these previously physically distant overhangs to each
other (Figure 3D). After reversal of cross links and DNA
TABLE 1 | FOXP2 cloned promoter (TSS) sequences used for reporter assays.
Element Size
(bp)
Start
(hg19)
End
(hg19)
Mean
conservation
(phastCons)
TSS1 1,791 113,724,817 113,726,609 0.34
TSS2 4,104 114,051,220 114,055,324 0.78
TSS3 1,006 114,055,454 114,056,459 0.93
extraction, the ligated ends can be detected via PCR amplification
of primers that span the two regions (i.e., promoter and putative
enhancer region) (Figure 3E). The presence of a PCR product
demonstrates that the two regions were in close physical contact
in the endogenous cell line.
Because TSS1 was strongly active in both HEK293 and SK-N-
MC cell lines, we identified the putative enhancer elements that
made contact with this promoter region. To this end, we designed
a Taqman probe to the 3′-end of the BglII restriction fragment
that contains TSS1 (Figures 3A,E). We then used reverse primers
within 45 restriction fragments (hereafter called ‘3C fragments’),
spanning four genomic regions that were considered likely to
contain enhancers regulating FOXP2 (Figure 3F). The majority
of enhancers can be found within 200 kb distance of a TSS (Li
et al., 2013) and cluster 1 targets enhancers in a 200 kb window
around TSS1, which spans the intergenic region between FOXP2
and PPP1R3A and the first intron of FOXP2 (Figure 3F: Cluster
1). Cluster 2 targets a 100 kb window around the alternative
start sites TSS2-4 of FOXP2 (Figure 3F: Cluster 2). Cluster 3
targets the intergenic region between the FOXP2 and the MDFIC
gene including the 3′-end of FOXP2 and the 5′-end of MDFIC
(including exons 1–3 and intron 4) (Figure 3F: Cluster 3).
This cluster includes a previously reported functional enhancer
that was suggested to regulate FOXP2 (Becker et al., 2015).
In addition, two target primers were designed to an intronic
region 460 kb downstream of the MDFIC gene (Figure 3F:
Cluster 4). We performed 3C in the seven human cell lines
described above, along with two EBV-transformed lymphoblast
cell lines which acted as a baseline reference since FOXP2
expression is low in EBV cells (Figure 1) and we do not
expect neuronal enhancers to be active in these blood-derived
cells.
Because the TSS1/promoter 1 is active in HEK293 cells
and they strongly express endogenous FOXP2, we first assessed
the interactions of the 45 different 3C fragments with TSS1
in these cells, compared to the ‘baseline’ EBV cell lines. We
mapped the relative enrichment of each fragment in HEK293
cells by first normalizing each interaction to a promoter-adjacent
fragment, which is in close linear sequence proximity to promoter
1 (located at −11 kb) (Figure 4A). We chose this fragment
because it showed the lowest variation across all cell lines, likely
caused by interactions facilitated by linear sequence proximity.
We further normalized to the interactions in the EBV control.
We compared the interactions in HEK293 cells with the EBV
baseline using two-sided t-tests and adjusted for multiple testing
by Benjamini-Hochberg correction. Eleven fragments (−37, 70,
329, 330, 346, 353, 604, 621, 706, 772, and 843) displayed
significant enrichment in HEK293 cells (Figure 4B, Table 2
and Supplementary Table S4), suggesting that they physically
interact with TSS1/promoter 1.
Unlike HEK293 cells, SK-N-MC and PFSK1 cells are neuron-
derived cell lines, but all three cell lines endogenously express
FOXP2 (Figure 1). As such, we mapped the relative enrichment of
the 45 3C fragments in SK-N-MC and PFSK1 cells to determine
if the pattern observed in HEK293 cells was conserved in these
other FOXP2 expressing neuronal cell lines. Thirteen regions
in SK-N-MC and six regions in PFSK1 cells were significantly
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FIGURE 3 | Chromatin conformation capture (3C) design for the FOXP2 gene locus. (A) Possible enhancer elements (blue blocks) are distant to their target
promoters (red block and arrow) on a linear representation of the genome. Specific target primers (black arrows) are designed at BglII restriction sites (black dotted
lines). (B) In living cells the genome is folded by proteins (green spheres) and active enhancers contact their target promoters. The chromatin packed genome is
cross-linked in this state and digested with BglII restriction enzymes. (C) The genomic fragments and DNA overhangs remain in physical proximity. The DNA is
diluted to favor proximity ligations between these genomic fragments. (D) Genomic fragments that were distant in the linear genome are ligated to form one short
DNA ligation product. (E) The primers that were distant in the genome are now close enough to amplify from the ligation product. (F) The genomic location of the
FOXP2 gene. The gene structure of FOXP2 and the neighboring genes PPP13RA and MDFIC are shown in dark blue. The anchor point primer is located at the distal
promoter 1 and shown in red. The 3C target primers (depicted in blue) were designed to cluster at four locations of the gene locus: Cluster 1 is around the anchor
point at TSS1. Cluster 2 is clustered around the downstream promoters TSS2-4. Cluster 3 is located at the downstream intergenic region between the FOXP2
3′UTR and MDFIC. Cluster 4 is downstream of the MDFIC gene. FOXP2 TSS1 is located at nucleotide 113,726,365 of the human genome in chromosome 7 (hg19).
The 3C primers (blue bars) were designed just upstream of the predicted BglII restriction sites.
enriched (Figure 4C and Table 2). A number of these regions
were shared between SK-N-MC and PFSK1 cells (region −39,
−37, 53, 604, 843), between SK-N-MC and HEK293 cells (−37,
70, 329, 330, 604, 706, 843), between PFSK1 and HEK293 cells
(−37, 604, 843), or between all three cell lines (−37, 604, 843)
and thus may represent common enhancer regions used in
cells endogenously expressing FOXP2. Two regions (−39 and
53) were significantly enriched in both neuronal cell lines, but
not in HEK293 cells, which may point to neuronal specific
activity. In total we detected eighteen chromatin interactions
between genomic regions and TSS1/promoter 1 in FOXP2
expressing cell lines, which were not observed in lymphoblast
cells (EBVs).
To determine if these chromatin interactions were unique to
FOXP2 expressing cell lines we also measured the 3C relative
enrichment in four neuroblast cell lines for which endogenous
FOXP2 could not be detected; KELLY, IMR32, SH-SY5Y and SK-
N-AS cells (Figure 4D and Supplementary Table S4). Many of
the peaks of enrichment observed in the FOXP2 positive cells
lines (Figures 4B,C), were also present in the FOXP2 negative
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FIGURE 4 | Chromatin conformation capture (3C) interaction landscape at the FOXP2 gene locus. Chromatin interactions at the FOXP2 gene measured by
chromatin conformation capture (3C). (A) Schematic representation of the genomic locus of PPP1R3A, FOXP2, and MDFIC. The indicated promoters (TSSs; arrows)
and 3′UTR (black bar) align with the data points of the following 3C graphs. (B–D) The relative interaction frequencies of genomic fragments to the promoter anchor
point are shown according to their distance to the TSS. (B) Chromatin interactions in HEK293 and EBV cell lines. (C) Interactions in neuronal-like FOXP2 positive cell
lines SK-N-MC and PFSK1. (D) Interactions in neuronal-like FOXP2 negative cell lines KELLY, IMR32, SH-SY5Y, and SK-N-AS. For all sections, the cross-linking
frequencies for each target primer were normalized to the cross-linking frequency of the target primer at –11 kb (internal normalization). The cross-linking frequency
for each target primer was normalized to the average cross-linking frequency of three measurements in two EBV lymphoblast cell lines (between sample
normalization). All interactions were determined in three biological replicates. Significance was calculated using two-tailed student t-tests. P-values were corrected
for the amount of tested genomic fragments using Benjamini-Hochberg correction. ∗p-value < 0.01; ∗∗p-value < 0.001.
cells (Figure 4D). However, overall, the enrichment observed in
FOXP2 negative cells was much weaker than in FOXP2 positive
cell lines.
In Silico Prediction of Enhancer
Elements within 3C Fragments
The 3C fragments at −37, 330, and 843 showed the strongest
and most consistent enrichment in the FOXP2 positive cell
lines (Figures 4B,C). However, since these interactions were
detected in human cell lines, we used publicly available chromatin
interaction data (Hi-C) of human post-mortem samples (Won
et al., 2016; Zhang et al., unpublished) to evaluate the interactions
in fetal and adult brain tissue. We visualized chromatin
interactions in the browser application supplied by YUE lab
(Wang et al., unpublished). In fetal cortical tissue, chromatin
interactions between TSS1 and 3C fragments −37, 330, and 843
can be observed (Supplementary Figure S1). In adult cortical
tissue, these interactions are weaker and comparable to the
background dynamics of chromatin interactions at this genomic
locus. Thus, the public data confirms the presence of the 3C
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TABLE 2 | Significant 3C fragment interactions in FOXP2 expressing cell lines.
HEK293 SK-N-MC PFSK1
3C-fragment Mean interaction
frequency
adjusted
p-value
Mean interaction
frequency
adjusted
p-value
Mean interaction
frequency
adjusted
p-value
−59 3.99 1.23E−01 2.84 4.33E−03 0.99 4.61E−01
−39 15.69 5.50E−02 15.95 3.35E−06 10.01 5.72E−03
−37 53.64 3.19E−03 21.55 6.97E−03 12.10 2.27E−03
13 3.13 1.08E−01 17.86 4.09E−03 3.44 1.15E−01
17 0.62 2.93E−01 3.06 2.47E−03 0.70 4.86E−01
53 10.53 6.25E−02 21.08 3.24E−04 7.69 1.06E−03
70 5.93 1.97E−03 12.33 1.13E−04 3.10 3.59E−01
329 9.22 2.68E−04 13.77 3.46E−04 1.99 5.50E−01
330 45.28 4.86E−03 65.26 5.37E−04 8.56 1.10E−01
335 2.97 4.79E−02 3.65 5.63E−04 0.98 9.06E−01
342 0.70 1.46E−01 1.14 3.02E−01 0.19 3.66E−03
346 32.82 1.57E−03 62.29 1.68E−02 12.77 5.22E−02
353 5.24 3.01E−03 6.79 3.37E−02 2.05 6.79E−02
604 60.15 3.55E−03 0.00 1.77E−23 9.88 8.01E−03
621 39.55 9.72E−03 0.67 2.56E−01 3.94 1.46E−02
706 7.94 1.26E−03 16.26 2.43E−03 0.88 3.65E−01
772 32.41 3.18E−06 1.00 1.00E+00 2.80 3.60E−01
843 67.39 4.68E−04 83.28 1.68E−08 19.30 7.16E−03
Bold represents significant p-values (p < 0.01).
interactions with TSS1 and suggests that they are present in the
developing human brain.
Because our 3C approach utilized the BglII restriction enzyme,
it produced 3C fragments of between 1 and 10 kb. Enhancer
regions are typically only a few hundred nucleotides in size
(Adam et al., 2015), making it necessary to narrow down the
likely position of the putative enhancers within each enriched 3C
fragment. To identify putative enhancer elements within these
large regions we used functional genomic annotations imputed
from twelve epigenetic marks (eleven histone modifications
and DNase hypersensitivity) mapped in human neuronal tissue
by the Roadmap Epigenomics Project (Bernstein et al., 2010;
Ernst and Kellis, 2015; Roadmap Epigenomics et al., 2015).
Active neuronal enhancers were predicted by strong histone-3-
lysine-4-monomethylation (H3K4Me1) and histone-3-lysine27-
acetylation (H3K27Ac) within the 3C fragments at 330 and 843 kb
(Table 3). The 3C fragment at−37 kb encompassed a weak neural
enhancer, predicted by strong H3K4Me1 and weak H3K27Ac.
In some neuronal Roadmap Epigenomics samples, parts of the
same fragment were annotated as an active TSS, predicted by an
absence of H3K4Me1 and strong histone-3-lysine-9-acetylation
(H3K9Ac). In this way, we identified smaller putative enhancer
regions within the 3C-interacting fragments.
Putative Enhancer Activity Demonstrated
via Reporter Assays
Having identified putative enhancer regions via 3C and in
silico analysis, we next aimed to verify the ability of these
regions to enhance gene expression using reporter assays. We
cloned the putative enhancer regions (Table 4) upstream of a
TABLE 3 | Epigenetic marks within 3C fragments.
3C fragment Positive enrichment
(p-value)
Roadmaps neuronal
functional element
(hg19 coordinates)
HEK293 SK-N-MC
−37 <0.001 N.S. Active TSS
(113688600–113688799),
Weak enhancer
(113688002–113689199)
330 <0.008 <0.001 Active enhancer
(114057400–114057799)
843 <0.001 <0.001 Active enhancer
(114569600–114570599)
minimal promoter (minP) and firefly luciferase reporter gene
(Figure 5A). We compared reporter gene expression from
these constructs with equivalent constructs lacking an enhancer
element (Figure 5A). The putative enhancer located within 3C
fragment −37 was able to strongly and significantly increase
reporter gene expression in both HEK293 and SK-N-MC cell
lines (Figure 5B). The putative enhancer located within 3C
fragment 330 strongly and significantly drove expression in
HEK293 cells, but not SK-N-MC cells. Finally, the putative
enhancer located within 3C fragment 843 was not able to enhance
reporter gene expression in either cell line (Figure 5B).
Regulation of the FOXP2 Promoter and
Enhancers by Transcription Factors
Herein we have shown that the FOXP2 TSS1/promoter 1 is
active in HEK293 and SK-N-MC cells, and identified putative
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TABLE 4 | Cloned putative enhancer regions.
Element Size
(bp)
Start
(hg19)
End
(hg19)
Mean conservation in
100 vertebrates
(phastCons)
Enhancer −37 774 113688009 113688782 0.023
Enhancer 330 1801 114056845 114058646 0.891
Enhancer 843 3958 114568454 114572411 0.111
FIGURE 5 | Enhancer activity in HEK293 and SK-N-MC. (A) The identified
putative enhancer elements were cloned upstream of the minimal promoter in
a firefly luciferase reporter gene construct. (B) Relative luciferase activity of
enhancer elements driving firefly luciferase gene expression in HEK293 and
SK-N-MC cells. The luciferase constructs containing the enhancers and the
control vector with the minimal promoter (minP) only were each co-transfected
with a control vector expressing the renilla luciferase under the control of the
HSV-TK promoter. The firefly luciferase signal was divided by the renilla signal
to derive the relative luciferase activity. The activity for each luciferase
construct was normalized for the activity observed for the minimal promoter
(minP). The constructs were measured in two independent experiments in a
total of six biological replicates, with the exception of element 843 in SK-N-MC
cells, which was measured in one experiment in three biological replicates.
The significance of the difference between each construct and minP was
determined with two-way ANOVA and post hoc LSD testing. ∗∗p < 0.001.
enhancer regions that make physical contact with this promoter
and can enhance gene expression in reporter assays (enhancer
−37 and 330). In a previous study we also identified a putative
enhancer element downstream of FOXP2 at position 815 (named
‘Element 1’ in that study), which was disrupted in a child with
language impairment and could drive gene expression in both
HEK293 and SK-N-MC cell lines (Becker et al., 2015). Given
that little is known about the TFs that regulate the expression
of FOXP2, we set out to determine if these three enhancer
regions or the FOXP2 promoters themselves could be regulated
by selected TFs. TFs often regulate their own expression in
positive or negative feedback loops (Crews and Pearson, 2009;
Bhatia et al., 2013), and thus we first tested if FOXP2 protein was
capable of auto-regulation via interaction with TSS1/promoter
1 or enhancers −37, 330, and 815. Given its close homology to
FOXP1 and FOXP4 and their overlapping expression patterns, we
also tested these other FOXP family members for their ability to
regulate gene expression via interaction with these regions. Lastly,
the TBR1 TF displays an overlapping expression pattern with
FOXP2 and these proteins are known to interact to regulate gene
expression (Deriziotis et al., 2014). As such we also asked if TBR1
was able to regulate FOXP2 expression, either in the presence or
absence of CASK, a co-activating factor that interacts with TBR1
to regulate genes underlying cortical development (Hsueh et al.,
2000; Deriziotis et al., 2014).
A small but significant increase in reporter gene expression
was observed when either FOXP2 or FOXP1 were introduced
into cells alongside the TSS1/promoter 1 fragment (Figure 6A,
left panel). No increase was observed when TBR1 or CASK alone
were introduced, but when these co-factors were introduced
together to the same cells, they resulted in a significant increase
in the reporter gene expression driven by the TSS1/promoter 1
(Figure 6A, right panel). From these reporter gene assays, we can
conclude that FOXP2, FOXP1 and TBR1-CASK can drive gene
expression from the FOXP2 TSS1/promoter 1 region.
To determine if these TFs could also drive gene expression
by interacting with the three identified FOXP2 enhancer regions,
we transfected the same set of TFs into cells alongside reporter
constructs containing enhancer region−37, 330 or 815 upstream
of a minimal promoter and the firefly luciferase reporter gene
(Figure 6B). Co-transfection with FOXP2 or FOXP1 led to a
significant increase in expression driven by enhancers −37 and
815 (Figure 6B, left panel). FOXP4 significantly increased gene
expression when enhancer −37 was present and led to a small
but statistically significant decrease in expression in the presence
of enhancer 330 (Figure 6B, left panel). TBR1 or CASK alone
led to a small but statistically significant reduction in expression
driven by enhancer −37 and TBR1 alone also reduced gene
expression via enhancer 330 (Figure 6B, right panel). However,
co-transfection of TBR1 and CASK resulted in a significant
increase in reporter gene expression, driven by enhancer −37
(Figure 6B, right panel). Thus, FOXP2, FOXP1, FOXP4, and
TBR1-CASK can all influence gene expression by interacting with
one or more of the identified FOXP2 enhancer elements.
DISCUSSION
Herein we describe the first systematic exploration of enhancer
regions of human FOXP2. Our data show that TSS1 is an active
promoter in human cell lines and identify eighteen different
genomic regions that are in physical contact with this promoter
across the cell lines tested, which differ in origin and endogenous
FOXP2 expression. We show that two of these regions (located
37 kb upstream and 330 kb downstream of TSS1, respectively)
are able to enhance gene expression in reporter assays. We
also show that these regions, along with a previously identified
putative enhancer (located 815 kb downstream of TSS1) and the
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FIGURE 6 | Regulation of FOXP2 promoter and enhancers by transcription factors. Relative luciferase activity of promoter elements (A) or enhancer elements
(B) after co-transfection with FOXP2, FOXP1, FOXP4, TBR1, CASK and the combination of TBR1 with CASK in HEK293 cells. The renilla luciferase control plasmid
was used for internal normalization. An empty pcDNA4 vector (EMPTY) that did not express any transcription factors was included as a control. Note that HEK293
cells have been shown to endogenously express FOXP1, FOXP2, FOXP4, and CASK, but not TBR1 (Thul et al., 2017). The firefly luciferase signal was divided by the
renilla signal to derive the relative luciferase activity. The activity for each luciferase construct was normalized to the co-transfection condition using an empty
plasmid. Each combination was tested in three biological replicates. The statistical significance of the TF overexpression effect was determined with two-way ANOVA
and post hoc LSD testing for each construct. ∗p-value < 0.05.
TSS1 promoter, can all be regulated by FOXP family members.
Promoter 1 and the 37 kb upstream enhancer are also regulated
by the TBR1/CASK complex.
Of the three TSSs tested via reporter assays, only TSS1 was
active in HEK293 and SK-N-MC cell lines and as such we used
this promoter to identify physical interactions and map enhancer
regions. TSS2 and TSS3 were not significantly different from
the baseline (minimal) promoter. This is consistent with what
has been previously observed in human cell lines (Schroeder
and Myers, 2008). Thus, TSS1 seems to be a key promoter
of FOXP2 expression, both in neuronal (SK-N-MC) and non-
neuronal (HEK293) human cells. However, these experiments
were carried out using in vitro cell lines and as such we could
not capture the full range of conditions under which these TSSs
would be functional. Indeed, TSS2-3 have been shown to be active
in human tissues including the basal ganglia, trachea and colon
(Schroeder and Myers, 2008).
We compared the physical interactions of enhancers in
neuronal and non-neuronal cell lines, with and without
endogenous FOXP2 expression. Cells that had endogenous
FOXP2 expression (HEK293, SK-N-MC, and PFSK1) showed
comparable patterns despite one of the cell lines being non-
neuronal. Only two regions (located 39 kb upstream and 53 kb
downstream) showed significant interaction in the neuronal
FOXP2 positive cell lines that were not seen in the non-
neuronal FOXP2 positive line. This could point to a neuron
specific function for these putative enhancers, however, further
experimental work such as testing in more neuronal and
non-neuronal cells/tissues and functional validation of these
enhancers is required to demonstrate if this is indeed the
case. When comparing all the FOXP2 positive and FOXP2
negative cell lines, many of the same regions were significantly
enriched, however, the magnitude of the relative enrichment
was substantially lower in FOXP2 negative cells. Thus it may be
that in cells that do not express FOXP2, these enhancer regions
make contact with TSS1 less frequently, or that the interactions
are less stable, possibly due to a lack of stabilizing TF complex
formation (Ong and Corces, 2014; Allen and Taatjes, 2015).
A limitation of this study is that the 3C interactions were obtained
in immortalized human cell lines. However, Hi-C undertaken in
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human fetal brain supported contacts between TSS1 and the key
regions we identified (3C fragments: −37, 330, and 815) (Wang
et al., unpublished), suggesting that these cell line-identified
interactions are also present in the developing human brain.
Two strong enhancers were identified within the 3C fragments
located 37 kb upstream and 330 kb downstream of FOXP2 TSS1.
Enhancer 330 is evolutionarily conserved across vertebrates,
whereas enhancer 37 shows low conservation, even across
primates. Evolutionary conservation can be regarded as the result
of functional constraint on sequence variety (Ureta-Vidal et al.,
2003; Miller et al., 2004) and highly conserved enhancers are
likely to drive target gene expression across related species. Thus,
we predict that the enhancer region located 330 kb downstream
of TSS1 is also likely to be a functional enhancer in non-human
species where it is highly conserved such as primates, mice,
and songbirds. Indeed, pronuclear injection of enhancer 330
into mice results in forebrain expression of a reporter gene at
embryonic day E11.5 (Visel et al., 2007). This demonstrates that
enhancer 330 is able to drive expression in the mouse brain,
and given its conservation, points to a possible role in driving
early forebrain FOXP2 expression in humans. The presence of
an evolutionary non-conserved enhancer at 37 kb upstream may
suggest that this regulatory region has changed on the human
lineage. Comparative studies of the ability of this enhancer to
drive expression would show if it has gained function over recent
evolution. If so, determining which specific aspects of FOXP2
expression it regulates could give insight into how evolution may
have shaped the role of this gene through modification of its
expression pattern.
We showed that FOXP2 is capable of auto-regulation,
increasing expression via interactions with promoter 1 (TSS1)
and the enhancers located 37 kb upstream and 815 kb
downstream of TSS1. Positive auto-regulatory loops such as
this can enable rapid amplification of a protein product to
maintain expression at stable plateau levels (Bateman, 1998)
and auto-regulation has been described for developmental
(Bateman, 1998; Di Gennaro et al., 2013; Mead et al., 2013) and
neurodevelopmental TFs (Meredith et al., 2009). Thus, our data
suggest that once expressed, FOXP2 contributes to maintenance
of its own expression via positive auto-regulation. FOXP1 showed
the same capacity for regulation as FOXP2, increasing expression
via interaction with promoter 1, enhancer−37 and enhancer 815.
FOXP4 only drove expression from enhancer −37. Thus FOXP2
is also regulated by other members of the FOXP subfamily.
Although they have several sites of independent expression (such
as in different layers of the cortex), it is notable that FOXP2 is co-
expressed with FOXP1 in the thalamus, hypothalamus and basal
ganglia of multiple species (Takahashi et al., 2008b; Mendoza
et al., 2015). FOXP4 expression is strong during development
and overlaps with FOXP2 in the ganglionic eminences, cortical
plate and thalamus (Takahashi et al., 2008a). In adult brains of
multiple species FOXP4 is co-expressed with FOXP2 in Purkinje
cells, thalamus and the inferior olives (Takahashi et al., 2008a;
Mendoza et al., 2015). Given that FOXP1 and FOXP4 are capable
of heterodimerisation with each other as well as with FOXP2 in
order to regulate gene expression (Li et al., 2004; Sin et al., 2015),
these proteins may contribute to the auto-regulatory mechanisms
of FOXP2 in the co-expressed brain regions and/or regulate
FOXP2 independently.
In our assays, we also showed that the combination of the
TBR1 TF and its cofactor CASK were able to regulate expression
from promoter 1 and enhancer −37. TBR1 or CASK alone did
not increase gene expression in these experiments suggesting
that it was the combined action of this protein complex that
resulted in regulation. The expression pattern of TBR1 partially
overlaps with FOXP2, both being found in the olfactory bulb
and neurons in the developing cortical plate and adult cortical
layer VI (Hevner et al., 2001; Hisaoka et al., 2010; Willsey
et al., 2013). CASK has been shown to be important for TBR1
activity and the TBR1/CASK complex is involved in regulation
of genes underlying cortical development, such as the neural
extracellular matrix gene RELN and the NMDA receptor subunit
2b (GRIN2b) (Wang et al., 2004; Hsueh, 2006). It was previously
shown that FOXP2 and TBR1 are able to interact to co-
regulate gene expression (Deriziotis et al., 2014). Taken together
these data suggest that TBR1 has the capacity to modulate
FOXP2 expression levels (via interaction with CASK) however,
demonstration of TBR1 binding to these regions, e.g., via ChIP
experiments in brain tissue, would be valuable to show direct
regulatory effects.
In the current study we were only able to explore a limited
number of fragments in and around the FOXP2 locus, given
the candidate 3C-qPCR approach. Enhancers may be located
megabases from the promoters they regulate. While we could
demonstrate physical interactions as far as ∼0.85 Mb from
TSS1, there may also be enhancers located further upstream or
downstream of TSS1 that are important for FOXP2 expression.
The genome is partitioned into topological associated domains
that are evolutionarily conserved, stable during development
and thought to define regulatory and physically interacting
genomic units (Dixon et al., 2012). Dynamic enhancer contacts
can take place within these topological domains, but not
across their topological boundaries (Dixon et al., 2012). All 3C
fragments investigated in this study were located within the
topological domain that contains the FOXP2 gene. However,
the domain spans ∼2.4 Mb (GRCh37/hg19 chromosomal
coordinates: chr7:113382764–115772764) and thus contains
sequence that was not covered in our 3C experiments,
including the PPP1R3A gene upstream of FOXP2 and the
downstream region encompassing the MDFIC and TFIC genes.
Because we used a candidate approach to map physical
interactions with TSS1 our data represent a systematic,
yet incomplete mapping of FOXP2 enhancers. They should
therefore be considered a starting point for further enhancer
identification to allow a complete understanding of the spatio-
temporal regulation of FOXP2, for example through an
extension of the 3C approach, or the application of high-
throughput 3C-sequencing based methods (Nagano et al.,
2013; Mifsud et al., 2015). Although not a saturation study
of the FOXP2 topological domain, this work gives insight
into the regulatory elements that may be controlling FOXP2
expression, and their transcriptional regulation. Defining the
regulatory mechanisms governing FOXP2 and the molecular
pathways upstream of this gene are crucial to elucidate its
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contributions to the development and functions of neuronal
circuitry underlying speech and language.
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FIGURE S1 | Chromatin interactions obtained from publicly available Hi-C data in
neuronal tissue samples. Chromatin interactions at chromosome 7 between
nucleotide 113350000 and 114640000 (hg19) determined via Hi-C were
visualized in the “Compare Hi-C” browser application
(http://promoter.bx.psu.edu/hi-c/compare.php; last accessed on 05.01.2018)
supplied by the YUE lab (Wang et al., unpublished). The middle panel displays the
location of FOXP2 and the neighboring genes PPP1R3A and MDFIC. The position
of the FOXP2 promoters at TSS1, TSS2, and TSS3 and the putative enhancers
−37, 330, 815, and 843, are annotated. The top panel shows the heat map of
chromatin interactions in a sample of human fetal cortical plate tissue (Won et al.,
2016) and the bottom panel shows the heat map of chromatin interactions in a
sample of human adult cortex tissue (Zhang et al., unpublished). Color intensity
indicates the strength of the measured chromatin interaction between two distant
regions at a resolution of 10 kb. In the fetal cortical plate, TSS1 of FOXP2 shows
stronger interactions to genomic regions at enhancers −37, 330, and 843 than to
other regions in this genomic locus (black arrows). In the adult cortex, the
chromatin interactions between TSS1 and these regions were generally weaker
(black arrows). The dashed lines indicate the interaction between 10 kb blocks
containing the elements of interest.
TABLE S1 | ChIP-qPCR Primers.
TABLE S2 | Primers used for 3C-qPCR.
TABLE S3 | Primers used to clone promoter and enhancer
regions.
TABLE S4 | Chromatin conformation capture (3C) fragment
interactions.
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